Semaglutide-Induced Rapid Weight Loss Linked to Rare Cardiac Device Malfunction
Background
While obesity is often managed effectively with GLP-1 receptor agonists like semaglutide, patients with pre-existing cardiac conditions requiring implantable cardioverter defibrillators (ICDs) face unique considerations. The potential mechanical complications of rapid weight loss on the stability and function of these life-sustaining implanted devices are not widely recognized or systematically studied.
Study Design
This study presents a case report detailing the experience of a 52-year-old woman with cardiac sarcoidosis and a dual-chamber implantable cardioverter defibrillator (ICD). She was treated with semaglutide for refractory obesity, presenting with an initial body mass index (BMI) of 40.1 kg/m². The abstract did not specify the exact semaglutide dosing protocol, but it was administered to achieve significant weight reduction.
Results
Following semaglutide treatment, the patient experienced a rapid and substantial weight loss of 25 kg. This significant reduction in body mass led to the development of painful device mobility and subsequent right ventricular lead dysfunction. A chest X-ray confirmed lead entanglement, a condition consistent with Twiddler syndrome, where the ICD rotates within its subcutaneous pocket, causing leads to twist and malfunction. The lead extraction procedure was complicated by cardiac tamponade, a life-threatening condition, but she recovered and successfully underwent reimplantation of a single-chamber ICD. This case highlights a direct link between rapid weight loss and a rare, severe mechanical complication in patients with cardiac devices.
Key Findings
- A 52-year-old woman with refractory obesity (initial BMI of 40.1 kg/m²) and an ICD developed complications after semaglutide treatment.
- She experienced a rapid and substantial weight loss of 25 kg, which subsequently led to increased mobility of her implanted ICD within its pocket.
- Diagnosis of Twiddler syndrome was confirmed by chest X-ray, showing lead entanglement and resulting in right ventricular lead dysfunction.
- The complication necessitated lead extraction, which was complex due to cardiac tamponade, followed by successful ICD reimplantation.
Why It Matters
This case report highlights a critical, albeit rare, adverse event associated with rapid weight loss induced by GLP-1 receptor agonists in patients with cardiac implantable electronic devices (CIEDs). The finding suggests that substantial weight loss, such as the 25 kg observed, can increase generator mobility in the subcutaneous pocket, potentially leading to Twiddler syndrome. Clinicians prescribing GLP-1 receptor agonists for obesity in patients with CIEDs should be aware of this potentially life-threatening mechanical complication and consider closer monitoring or prophylactic measures. Further studies, including larger observational cohorts or prospective registries, are needed to quantify this risk and inform clinical guidelines.
semaglutide
Twiddler syndrome
obesity
cardiac implantable electronic device
case report
adverse event